NEW MJ NEWS

MariMed Announces Second Quarter 2023 Earnings Date

MariMed Inc. (“MariMed” or the “Company”), (CSE: MRMD), (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced it will report its second quarter 2023 financial results on August 2, 2023 after the markets close. Management will host a conference call on August 3, 2023 at 8:00 a.m. EST to discuss financial results.

A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q223 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website.

About MariMed
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, InHouse, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit https://marimedinc.com/.

Investor Relations Contact:
Steve West
Vice President, Investor Relations
Email: ir@marimedinc.com
Phone: (781) 277-0007

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Lexaria Bioscience Corp. (LXRP) Expands Pharmaceutical Division

Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for…

Global Consortium, Inc., (GCGX) is exploring opportunities in Canada

Global Consortium, Inc., is exploring opportunities in Canada Global Consortium, Inc., (GCGX)…

$IMLFF Announces Progress in Orofacial Pain Program

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program  InMed Pharmaceuticals Inc. (“InMed”)…

$AFI Signs Licensing Agreement With a Private Farm in Tennessee

Affinor Growers Signs Licensing Agreement With a Private Farm in Tennessee Affinor…